Dong-A Socio Holdings Co., Ltd. (000640.KS)

Dong-A Socio Holdings Co., Ltd. engages in the pharmaceutical business in South Korea and internationally. It offers Bacchus, Benachio, and Tempo; infection management products; imaging equipment, such as FX-V1 and CLS-S7 for surgery and diagnosis; and MEDIFLIX, a medical knowledge-sharing platform. The company provides business management services; CMO services, including pre-clinical study, clinical trial, and commercial production of antibodies and recombinant proteins; maintenance, repair, and operation; quarantine; and military logistics services; and packaging and parcel delivery services. In addition, it offers mineral water under the Gayasan Cheonnyeonsu brand; POCARI SWEAT; Narangd cider; Oronamin C; Oran-C bio-PET; and STP2104, an mRNA based COVID-19 vaccine, which is in phase I clinical trial. Further, the company engages in the construction of industrial facilities, such as bio, pharmaceutical, food, logistics warehouses, education/research facilities, work/sales facilities, and public facilities; provides design, maintenance, and asset development services. Additionally, it provides IT systems development and maintenance. The company was founded in 1932 and is headquartered in Seoul, South Korea.